Resources from the same session
Optimal positioning and sequencing of EGFR E20I inhibitors: Research perspectives for (neo-)adjuvant use and 1st line of advanced disease
Presenter: P. A. Jänne, US
Session: Session 5 – Optimising use of EGFR E20I mutations
Resources:
Slides
Webcast
Presentation of clinical cases of advanced NSCLC patients treated with immunotherapy and subsequent diagnosis of EGFR E20I mutations: Considerations of efficacy and safety
Presenter: S. M. Lim, KR
Session: Session 5 – Optimising use of EGFR E20I mutations
Resources:
Slides
Webcast